Drug to prevent breast cancer near approvalBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7160.697 (Published 12 September 1998) Cite this as: BMJ 1998;317:697
- Scott Gottlieb
- New York
A scientific advisory panel of the Food and Drug Administration (FDA) has overwhelmingly voted to recommend the approval of tamoxifen for reducing the incidence of breast cancer in healthy women with an increased risk of developing the disease.
In the carefully worded ruling, which is likely to be followed by the FDA, the panel stopped short of agreeing that the drug could actually prevent breast cancer over the long term, ruling that this has not yet been proved by clinical studies. The panel's deliberations highlighted some of the lingering uncertainty over whether healthy women should …
Log in using your username and password
Log in through your institution
Sign up for a free trial